Will. and morning, the ever. end you of us. position joining in everyone, tail for than We a stronger entered XXXX Good Thanks, thank
exceptionally data to prexigebersen promising AML We with expect XXXX. in and data have more even generate
our prexigebersen, to deliver number our to technology continue platform Beyond we that DNAbilize nanoparticle innovative robust to therapeutics important clinical programs cancer of directly RNAi across leverage a program development cells. advance
path forging believe give beat that a medicine We a will to in these fighting we chance cancers. are patients difficult-to-treat new DNA-powered
with with progress we lead I'll begin prexigebersen. have our candidate, made product
of relapsed meaningful or treatment II everything -- Note, treatment leukemia, the As you myeloid of of end of This essentially encouraged options. in available. venetoclax. Phase at currently to clinical the Stage the is already the have our and of continue by because these everything decitabine are be acute trial patients the armamentarium know, therapy combination from most line or prexigebersen we in of positive interim with II results treatment AML, for frontline
drug like patients. hope a these prexigebersen So to give can
II patients previously in multi-center decitabine and Phase open-label, untreated cohorts Stage of relapsed/resistant AML. in our Recall, trial of It AML. an with study two amended with and of II venetoclax two-stage, is in is prexigebersen an the study combination AML
the of includes The and two-drug combination third decitabine. relapsed/resistant are cohort who AML patients with prexigebersen intolerant treating or venetoclax-resistant
endpoint of hematologic includes incomplete complete number be the complete with partial patients complete primary with The will hematologic who this recovery remission, remission achieve recovery. study and which remission of
of evaluable recap, XX European venetoclax patients combination Cohort treated achieved, with I very we and least All EON there were guidelines of decitabine by a or were promising XXXX this newly-diagnosed As the secondary results in or adverse risk AML. in these at cohort one cycle patients prexigebersen, therapy. LeukemiaNet and
for with XX% and Prexigebersen of had In for remissions. was a complete evaluable of achieved well consistent decitabine tolerated, of which or XX% and/or significantly XX I completion patients response rate disease. treatment evaluable the Cohort combination The venetoclax XXX% Cohort is of total, the than patients, evaluable the of are AML. and generally high-risk further XX newly-diagnosed decitabine highlighted is treatment result secondary I with of and in complete remission very and both XX% partial were the treatment. of of AML achieved our patients XX% venetoclax. with adverse events of rating by remission, X to patients frontline rates for the higher difficult-to-treat patients or the evaluable This inclusion patients and classes patients treated
disease. were therapy. remission XXXX XX this of in the prexigebersen, refractory/relapsed evaluable Cohort and cohort one at decitabine AML for rate in treated The adverse cycle All patients or Cohort patients by In the to least risk II combination combination were in had of or rate with venetoclax refractory refractory/relapsed of complete treated the treatment XX% than AML. of X total, well patients XX% secondary relapsed treatment patients of and/or and achieved and or complete of AML. decitabine evaluable X XX partial were of is and guidelines venetoclax. XX% consistent higher and or XX% AEs ELN Prexigebersen XX% treatment. XX% and decitabine remission a II achieved with remission patients significantly for evaluable tolerated, patients complete with generally venetoclax remission, achieved patients patients evaluable stable X response was
patients this evaluable the highlighted and As patients. in result of with Cohort inclusion the newly-diagnosed further Bio-Path of I, Cohort rating is AML high-risk II by patients secondary
relapsed/refractory and Cohort interim is AML II chemotherapy treatment suboptimal. combination patients only demonstrated in from administered compelling are to was newly-diagnosed and high-risk, standard data Cohort efficacy not significantly Cohort current encouraging I current therapy a show and considered the Efficacy as initial that patients challenging but also population are in refractory/relapsed analysis particularly This Cohort are unsuitable prexigebersen-based signals of which I than safely therapies. II and for better options
of the and front. strength we and currently to We Food data, expedite fast to plan progress pursue look these or regulatory Administration FDA, apprised on of programs On breakthrough the our you designations. forward Drug U.S. track therapy keeping for
our fact our encourage that Bio-Path's listen I the website. which The to this are our by development prexigebersen discuss October, to need of have was event, heartwarming interim hematologic the deeply expert illuminating medical point leader highlight AML evolving these seen inspiring. of as population. for space and Having results not treatment We to support Cortes unmet were were clinical Dr. speakers. was was archive in patient guest key available of program this to Ohanian, simply Maro view our discussion mission as this physician and encouraged great both conviction oncology bolstering opinion the patients. in AML. results to specialists you and luminaries all this and the experts independent is a the true in engaging, hosted It in further In event Dr. that privileged underscored Jorge these we have relapsed magnitude landscape and on
targets now Bcl-X. Turning our which to program, BPXXXX
by for with chronic CLL for is patients. of treatment Bcl-X know, improved The cancers. AML poor responsible diagnosed AML. or high XX% you for of been to protein activity patients leukemia in and domain. survival cell has up shown untreated lymphocytic against neutralizing with As works has It Bcl-X is protein's correlated expression patients Venetoclax Bcl-X driving an and BHX anti-apoptotic all the prognosis
of exception some the due time. allogeneic over occurs mutation with often disease transplantation, hematopoietic cell domain relapse invariably to with treated BHX times However, patients
BPXXXX Bcl-X protein. targets also
However, and domain. messenger the not the BPXXXX is Bcl-X blocking activity RNA BHX based on
As venetoclax a result, could alternative believe that AML BPXXXX who we provide patients who including an received relapsed, have venetoclax previously for patients treatment.
a monotherapy weeks, commence over resulting dose The total is A with monotherapy cohorts and the of XX The assess in starting BPXXXX XX administered improved of be after completion evaluable AML eight in patients the a meter. over portion in of cycle doses will X+X combination with X days. design of treated and in patients. per will efficacy four per Phase will milligrams square of decitabine safety refractory/relapsed week treatment BPXXXX doses two standard with Ib study BPXXXX
in expect We coming study initial months. cohort this completion from the data readout and
ovarian will in provide trial and properties. in pancreatic from XXXX. of second evaluate centers and dose poor to to benefit several leading may and patients. We cancer safety it's early cohort. this we patients. readout and our in conducted cancer outcomes, such the have This cohort trial endometrial initially being at that with hope look Patients with study I/Ib BPXXX-A The and BPXXXX-A treat toolkit. clinical sharing prexigebersen, cancer, in cancers the our is a triple-negative is drug the turn modified breast [ BPXXXX-A let's Phase ] the therapeutic clinical with solid trial most substance Next, nanoparticle challenging product same tumor solid some completion ovarian, with to often enhanced of patients is (sic) including forward from endometrial, clinical tumors, recurrent diagnosed data for study today's
resistance. and taxol cancer promotes targets the to in cancer lung, the regulates cancer. overexpression Finally, many potential aberrant in a of let's review which activation liver resistance makes cells drug the processes including therapy numerous various STATX in tumor Its factor BPXXXX, resistance. contributes colorectal also metastasis with cancer and characterize target. a proliferation, migration ovarian STATX cancers, protein. progress tumor X-FU transcription such and malignancies and colon STATX and cells. role is STATX initiation, STATX Activation breast we've made as breast, ovarian, tumorigenic Its that pathway
liposome-incorporated displayed BPXXXX These in novel are results enhanced line Together, expression enhances cells with BPXXXX oligodeoxynucleotide is is antitumor cancer BPXXXX reduces therapy previous antisense advanced efficiently strongly combination sensitivity the a in that and results a ovarian to in STATX gemcitabine X-FU. and of solid breast tumors. and STATX activity these pancreatic suggest nominal plus with patients ductal adenocarcinoma. that work which for strategy taxol
to limited treatment particularly We indication in first excited launch cutting-edge options. are an has this validation challenging of especially therapy that our cancer in-human
turn our along financials that, balance a review the sheet Anthony? over program of brief for Price now I'll Anthony highlights. to with With
